

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
				Attorney Docket Number	HC-P02-060
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	2	of	2	Attorney Docket Number	HC-P02-060

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Bailey et al., "Sonic Hedgehog Paracrine Signaling Regulates Metastasis and Lymphangiogenesis in Pancreatic Cancer," <i>Oncogene</i> , Vol. 28(40), pp. 3513-3525 (2009).	
	CB	Berman et al., "Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours," <i>Nature</i> , Vol. 425, pp. 846-850 (2003).	
	CC	Brown et al., "Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells," <i>Breast Cancer Research</i> , Vol. 6(5), pp. R601-607 (2004).	
	CD	Coon et al., "Molecular Therapy Targeting Sonic Hedgehog and Hepatocyte Growth Factor Signaling in a Mouse Model of Medulloblastoma," <i>Molecular Cancer Ther.</i> , Vol. 9(9), pp. 2627-2636 (2010).	
	CE	Sulkes et al., "Docetaxel (Taxotere TM) in advanced gastric cancer: results of a phase II clinical trial," <i>Br. J. Cancer</i> , Vol. 70, pp. 380-383 (1994).	
	CF	Valone et al., "Phase Ia/Ib Trial of Bispecific Antibody MDX-210 in Patients with Advanced Breast or Ovarian Cancer that Overexpresses the Proto-Oncogene HER-2/ <i>neu</i> ," <i>Journal of Clinical Oncology</i> , Vol. 13(9), pp. 2281-2292 (1995).	
	CG	Weiner et al., "Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FcγRIII," <i>Cancer Research</i> , Vol. 55, pp. 4586-4593 (1995).	
	CH	Yauch et al., "A paracrine requirement for hedgehog signalling in cancer," <i>Nature</i> , Vol. 455, pp. 406-412 (2008).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.